The IMPROVE-AD study is funded by the National Heart, Lung, and Blood Institute
in the US. The study aims to understand how best to treat type B aortic dissection. It will include up to 1,100 patients from 60 hospitals across the United States and Canada. The trial is powered to demonstrate whether upfront thoracic endovascular repair (TEVAR) is superior to the standard of care of Medical Therapy and intervention when needed during follow up over 4 years. The entire study duration is 7 years with a planned completion in 2030.
BJS Academy>Surgical trials>IMPROVE AD: Randomiz...
IMPROVE-AD: Randomized trial for uncomplicated Type B Aortic Dissection
27 October 2025
Trials Video Vascular

Published on: 27 October 2025
Article ID: BJS-2025-0570
Related articles

Type B dissections: keeping it “uncomplicated” in a complicated world
Bianca Biersteker, Joost van der Vorst, Jacob Budtz-Lilly

Closing the treatment gap in knee osteoarthritis — the GEKO trial begins
Dr Raman Uberoi, Dr Anjali Shah, Dr Bhavisha Patel, Dr Loretta Davies, Professor Andrew Price, GEKO study group
Copied!
Connect

Copyright © 2026 River Valley Technologies Limited. All rights reserved.



.png)





.jpg)



